MMJ takes major step forward on phase 2 trials
MMJ PhytoTech (ASX:MMJ) has taken a major step forward on its journey to becoming a pharmaceutical player in the epilepsy space – confirming phase 2 trials for Q4.
It told its shareholders yesterday that following on from successful phase 1 trials in the first quarter this year that it was now in the process of designing phase 2 trials for its Gelpell PTL101 capsule, with the trial to be run out of Israel.
The phase 1 trial was a success for MMJ, where it successfully demonstrated that it had a better cannabidiol (CBD) and THC absorption rates than market-leading spray Sativex, from GW Pharmaceuticals.
This means the active ingredients are able to work faster than the market leading brand, although there is still water to go under the bridge still.
MMJ will be hoping the phase 2 trials confirm the product’s efficacy against other solutions on the market, with MMJ managing director Andreas Gedeon saying MMJ was truly unique in the space.
“While many other companies try and fail in attempting to reach this stage, our ability to compete with a large pharmaceutical player like GW results from the synergies of our vertically integrated global supply chain,” he said.
MMJ still has a long way to go before being matched to GW’s share price or market cap, so while competitive on product you should still take a cautious approach to making an investment decision in this company and seek professional financial advice.
MMJ operates several arms with a cultivation and extraction operation in Canada, a product development arm in Switzerland, and a R&D unit in Israel.
A phase 2 trial has the potential, the company said, to act “as a key catalyst” towards the commercial development of the PTL101 prescription drug.
The development of another drug would also be beneficial to those suffering from intractable epilepsy – with 100,000 children in the US alone suffering from the treatment-resistant category of the disease.
It is estimated that treatment remains ineffective for as many as 30% of sufferers, due to drugs failing to control the frequency of seizures or patients not being able to manage the side-effects of the drugs.
In other MMJ news, it told its shareholders that it in the final stretch of designing a phase 2 trial on its PTL201 drug, aimed at managing spasticity associated with multiple sclerosis.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.